{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:52:23Z","timestamp":1794469943242,"version":"4.9.1"},"reference-count":29,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are Food and Drug Administration- and European Medicines Agency-approved chimeric antigen receptor (CAR) T-cell therapies for relapsed\/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up are lacking. We conducted a retrospective study of 160 LBCL patients treated at the Fred Hutchinson Cancer Center with commercial liso- cel or axi-cel per standard of care. Using inverse probability of treatment weighting (IPTW) to mitigate treatment allocation bias and multivariable adjustments to minimize other sources of confounding, we assessed the impact of CAR T-cell product type on outcomes. Axi-cel was associated with significantly higher rates of cytokine release syndrome (CRS; grade [G]1+: adjusted odds ratio [aOR] =4.27; P=0.004; G2+: aOR=2.88; P=0.006), immune effector cell-associated neurotoxicity syndrome (ICANS; G1+: aOR=2.10; P=0.048), and immune effector cell-associated hematotoxicity (ICAHT; G1+: aOR=8.09; P&lt;0.001; G2+: aOR=3.86; P=0.001). Axi-cel was also associated with more frequent use of supportive care measures, such as tocilizumab (aOR=2.50; P=0.017), dexamethasone (aOR=2.77; P=0.007), and cefepime (aOR=3.37; P=0.001). We could not confirm statistically significant differences in the response rates and survival outcomes after liso-cel versus axi-cel (complete response: aOR=1.12; P=0.8; overall survival: adjusted hazard ratio [aHR] =1.34; P=0.3; progression-free survival: aHR=0.97; P=0.9; duration of response: aHR=0.89; P=0.7; cumulative incidence of relapse: aHR=0.92; P=0.8). In summary, although axicel was associated with greater toxicity requiring more intensive management, the response rates and survival outcomes were comparable between axi-cel and liso-cel.<\/jats:p>","DOI":"10.3324\/haematol.2024.287010","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:41:40Z","timestamp":1741840900000},"page":"2040-2054","source":"Crossref","is-referenced-by-count":15,"title":["Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up"],"prefix":"10.3324","volume":"110","author":[{"given":"Andrew J.","family":"Portuguese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yein","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoosh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Albittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre V.","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik L.","family":"Kimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Poh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude G.","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folashade","family":"Otegbeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Basom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian Vicky","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"78603","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023; 141(19):2307-2315.","DOI":"10.1182\/blood.2022018893"},{"key":"78604","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7):640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"78605","doi-asserted-by":"crossref","unstructured":"Abramson JS, Solomon SR, Arnason J. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023; 141(14):1675-1684.","DOI":"10.1182\/blood.2022018730"},{"key":"78606","unstructured":"U.S. Food and Drug Administration. Juno Therapeutics Inc., a Bristol-Myers Squibb Company. Breyanzi (lisocabtagene maraleucel) [package insert]. 2025. Publisher Full Text|"},{"key":"78607","unstructured":"U.S. Food and Drug Administration. Kite Pharma, Inc. Yescarta (axicabtagene ciloleucel) [package insert]. 2025. Publisher Full Text|"},{"key":"78608","unstructured":"U.S. Food and Drug Administration. Novartis Pharmaceuticals Corporation. Kymriah (tisagenlecleucel) [package insert]. 2025. Publisher Full Text|"},{"key":"78609","unstructured":"European Medicines Agency. Yescarta (axicabtagene ciloleucel). 2025. Publisher Full Text|"},{"key":"78610","unstructured":"European Medicines Agency. Breyanzi (lisocabtagene maraleucel). 2025. Publisher Full Text|"},{"key":"78611","unstructured":"European Medicines Agency. Kymriah (tisagenlecleucel). 2025. Publisher Full Text|"},{"key":"78612","doi-asserted-by":"crossref","unstructured":"Bishop MR, Dickinson M, Purtill D. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022; 386(7):629-639.","DOI":"10.1056\/NEJMoa2116596"},{"key":"78613","doi-asserted-by":"crossref","unstructured":"Gauthier J, Gazeau N, Hirayama AV. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood. 2022; 139(26):3722-3731.","DOI":"10.1182\/blood.2021014497"},{"key":"78614","doi-asserted-by":"crossref","unstructured":"Bachy E, Le Gouill S, Di Blasi R. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022; 28(10):2145-2154.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"78615","doi-asserted-by":"crossref","unstructured":"Sehgal A, Hoda D, Riedell PA. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022; 23(8):1066-1077.","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"78616","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"78617","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024; 143(5):404-416.","DOI":"10.1182\/blood.2023020854"},{"key":"78618","doi-asserted-by":"crossref","unstructured":"Smith SD, Reddy P, Sokolova A. Eligibility for CAR T-cell therapy: an analysis of selection criteria and survival outcomes in chemorefractory DLBCL. Am J Hematol. 2019; 94(4):E117-E116.","DOI":"10.1002\/ajh.25411"},{"key":"78619","doi-asserted-by":"crossref","unstructured":"Maloney DG, Kuruvilla J, Liu FF. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021; 14(1):140.","DOI":"10.1186\/s13045-021-01144-9"},{"key":"78620","doi-asserted-by":"crossref","unstructured":"Looka A, Qualls DA, Matthews D. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025; 9(3):455-462.","DOI":"10.1182\/bloodadvances.2024012992"},{"key":"78621","unstructured":"Team RC. R: A language and environment for statistical computing. 4.4.1. 2024."},{"key":"78622","doi-asserted-by":"crossref","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015; 34(28):3661-3679.","DOI":"10.1002\/sim.6607"},{"key":"78623","doi-asserted-by":"crossref","unstructured":"Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987; 82(398):387-394.","DOI":"10.1080\/01621459.1987.10478441"},{"key":"78624","doi-asserted-by":"crossref","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70(1):41-55.","DOI":"10.1093\/biomet\/70.1.41"},{"key":"78625","doi-asserted-by":"crossref","unstructured":"Roddie C, Neill L, Osborne W. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023; 7(12):2872-2883.","DOI":"10.1182\/bloodadvances.2022009019"},{"key":"78626","doi-asserted-by":"crossref","unstructured":"Epperla N, Feng L, Shah NN. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023; 16(1):111.","DOI":"10.1186\/s13045-023-01508-3"},{"key":"78627","doi-asserted-by":"crossref","unstructured":"Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010; 25(1):1-21.","DOI":"10.1214\/09-STS313"},{"key":"78628","doi-asserted-by":"crossref","unstructured":"Kamdar M, Solomon SR, Arnason J. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399(10343):2294-2308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"78629","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"78630","doi-asserted-by":"crossref","unstructured":"Juluri KR, Wu QV, Voutsinas J. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022; 6(7):2055-2068.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"78631","doi-asserted-by":"crossref","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021; 18(11):715-727.","DOI":"10.1038\/s41571-021-00530-z"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11977\/78182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11977\/78733","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11977\/78182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:21Z","timestamp":1794046101000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287010","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}